| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
254,921 |
421,551 |
1,262,027 |
1,480,093 |
| Total Sell Value |
$16,747,919 |
$26,516,522 |
$74,515,877 |
$82,888,946 |
| Total People Sold |
8 |
9 |
12 |
12 |
| Total Sell Transactions |
23 |
40 |
87 |
90 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pera Antonio R |
|
– • – |
2020-08-05 |
4 |
A |
$0.00 |
$0 |
D/D |
7,421 |
7,421 |
|
- |
|
| Walsh Patrick D |
Interim President and CEO |
• • – |
2020-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,050 |
20,096 |
|
- |
|
| Haughey Thomas |
Director |
– • – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,119 |
18,410 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
39,767 |
93,043 |
|
- |
|
| Walsh Patrick D |
Director |
– • – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,255 |
13,046 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
24,548 |
85,297 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
39,767 |
63,145 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,119 |
29,680 |
|
- |
|
| Nash David |
Director |
– • – |
2020-04-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,119 |
12,355 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2020-04-07 |
4 |
D |
$43.93 |
$6,326 |
D/D |
(144) |
60,749 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2020-04-07 |
4 |
D |
$43.93 |
$92,912 |
D/D |
(2,115) |
190,309 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2020-04-07 |
4 |
D |
$43.93 |
$17,396 |
D/D |
(396) |
53,276 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2020-04-06 |
4 |
D |
$43.22 |
$14,565 |
D/D |
(337) |
60,893 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2020-04-06 |
4 |
D |
$43.22 |
$141,848 |
D/D |
(3,282) |
192,424 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2020-04-06 |
4 |
D |
$43.22 |
$28,785 |
D/D |
(666) |
53,672 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2020-04-06 |
4 |
D |
$43.22 |
$26,451 |
D/D |
(612) |
23,378 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2020-03-31 |
4 |
D |
$40.74 |
$109,142 |
D/D |
(2,679) |
195,706 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2020-03-31 |
4 |
D |
$40.74 |
$22,488 |
D/D |
(552) |
54,338 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2020-03-31 |
4 |
D |
$40.74 |
$20,655 |
D/D |
(507) |
23,990 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2020-03-28 |
4 |
D |
$37.76 |
$158,743 |
D/D |
(4,204) |
198,385 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2020-03-28 |
4 |
D |
$37.76 |
$39,157 |
D/D |
(1,037) |
54,890 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2020-03-28 |
4 |
D |
$37.76 |
$35,985 |
D/D |
(953) |
24,497 |
|
- |
|
| Haughey Thomas |
Director |
– • – |
2020-03-04 |
4 |
B |
$45.05 |
$135,150 |
D/D |
3,000 |
11,291 |
2.39 |
- |
|
| Haughey Thomas |
Director |
– • – |
2020-03-03 |
4 |
B |
$45.18 |
$90,360 |
D/D |
2,000 |
8,291 |
2.39 |
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-08-20 |
4/A |
AS |
$68.18 |
$375,808 |
D/D |
(5,512) |
2,281,283 |
|
- |
|
722 Records found
|
|
Page 10 of 29 |
|
|
0.14 (0.21%) 
